InMode has provided preliminary Q2 revenue guidance of $95.2M–$95.4M, ahead of analyst expectations and demonstrating continued demand for its Morpheus8 RF microneedling and fractional-laser systems. The guidance arrives amid the Steel Partners takeover bid and competing CEO-led buyout, underscoring the underlying strength of the energy-device market.
Market
InMode Guides Q2 Revenue to $95.2M–$95.4M — Growth Resilience Amid Takeover Uncertainty
InMode's preliminary Q2 revenue guidance exceeds consensus, signaling sustained demand for RF and fractional-laser platforms despite acquisition turmoil.
1-YEAR MOVE
INMD
▲1.0%
| Ticker | Company | 1-year change |
|---|---|---|
| INMD | InMode Ltd. | +1.0% |
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
InMode guides Q2 revenue to $95.2M–$95.4M, signaling sustained demand for RF and fractional-laser platforms.
For practice owners, InMode's revenue resilience reflects sustained adoption of RF microneedling and fractional laser in medspa and surgical settings. The company's installed base and per-procedure pricing power remain intact despite competitive pressure from Cynosure, Cutera, and Lumenis. However, takeover uncertainty may delay new device placements and rebate negotiations; practices considering InMode capital equipment should clarify pricing and loyalty terms before deal closure, expected by year-end.
Source: original report ↗
Frequently asked questions
What is InMode's Q2 revenue guidance and how does it compare to expectations?
InMode guided Q2 revenue to $95.2M–$95.4M, exceeding analyst consensus. This guidance signals sustained demand for the company's Morpheus8 RF microneedling and fractional-laser platforms despite ongoing acquisition uncertainty.
Should medspa owners buy InMode equipment now or wait for the takeover to close?
Practices considering InMode capital equipment should move quickly to clarify pricing, rebate terms, and loyalty agreements before deal closure, expected by year-end. Takeover uncertainty may delay new placements and complicate negotiations, so locking in terms now protects your investment.
Is RF microneedling and fractional laser demand still strong in 2024?
Yes—InMode's revenue beat reflects sustained adoption of RF microneedling and fractional-laser systems in both medspa and surgical settings. Demand remains resilient despite competitive pressure from Cynosure, Cutera, and Lumenis.
What is Steel Partners' takeover bid for InMode and when will it close?
Steel Partners launched a takeover bid for InMode, which is competing with a CEO-led buyout. The deal is expected to close by year-end, but uncertainty around the outcome may impact device pricing and availability during the interim period.
How does InMode's pricing power compare to competitors like Cynosure and Lumenis?
InMode maintains per-procedure pricing power and an intact installed base despite competitive pressure from Cynosure, Cutera, and Lumenis. The company's Morpheus8 platform continues to drive strong adoption and revenue growth.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.